Sun Pharma to acquire Russia's JSC Biosintez; shares up

“With this move, we plan to acquire the product portfolio and local manufacturing capability in Russia which would help in expanding our presence in Russia and serving Russia pharmaceutical market more effectively,” Sun Pharma said in a statement.

Sun Pharma to acquire Russia's JSC Biosintez; shares up
The deal will involve cost acquisition of approximately RUB 1526 million ($24 million).Photo: Reuters/ Danish Siddiqui
Written By: ZeeBiz WebTeam
Updated: Wed, Nov 23, 2016
10:10 am
Mumbai, ZeeBiz WebDesk
RELATED NEWS
Stocks in Focus on June 4: BPCL, HDFC Life to Pharma Companies; here are expected newsmakers of the day Stocks in Focus on June 4: BPCL, HDFC Life to Pharma Companies; here are expected newsmakers of the day
Stocks in Focus on November 22: CSB bank, RITES to BHEL; here are the 5 Newsmakers of the Day Stocks in Focus on November 22: CSB bank, RITES to BHEL; here are the 5 Newsmakers of the Day
Anil Singhvi’s Strategy September 6: Market Trend is Neutral; Metal sector is Positive; NBFC is Negative Anil Singhvi’s Strategy September 6: Market Trend is Neutral; Metal sector is Positive; NBFC is Negative

Sun Pharmaceuticals on Wednesday said that it has entered into an agreement to acquire 85.1% of JSC Biosintez – a Russian pharma company.

“With this move, we plan to acquire the product portfolio and local manufacturing capability in Russia which would help in expanding our presence in Russia and serving Russia pharmaceutical market more effectively,” Sun Pharma said in a statement.

The deal will involve cost acquisition of approximately RUB 1526 million ($24 million). Sun Pharma will also assume a debt of about $ 36 million as a part of the transaction.

Shares of Sun Pharma was trading at Rs 693.60 per share on BSE, up Rs 4 or 0.56%. 

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.